Cargando…

The core role of macrophages in hepatocellular carcinoma: the definition of molecular subtypes and the prognostic risk system

Background: In patients with hepatocellular carcinoma (HCC), the tumor microenvironment (TME) is resistant to immunotherapy because of its specificity. It is meaningful to explore the role of macrophage, which is one of the most abundant immune cells in the TME, in cellular communication and its eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qiaona, Lin, Yunshou, Yu, Wenguan, Chen, Xiaogang, He, Qingqing, Ye, Zhiyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491020/ https://www.ncbi.nlm.nih.gov/pubmed/37693905 http://dx.doi.org/10.3389/fphar.2023.1228052

Ejemplares similares

Classification molecular subtypes of hepatocellular carcinoma based on PRMT-related genes
por: Liu, Liwen, et al.
Publicado: (2023)

Molecular subtypes and scoring tools related to Foxo signaling pathway for assessing hepatocellular carcinoma prognosis and treatment responsiveness
por: Tu, Sheng, et al.
Publicado: (2023)

Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma
por: Yuan, Yi, et al.
Publicado: (2023)

OSlihc: An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma
por: An, Yang, et al.
Publicado: (2020)

Molecular mechanism of Ganji Fang in the treatment of hepatocellular carcinoma based on network pharmacology, molecular docking and experimental verification technology
por: Yang, Miaolun, et al.
Publicado: (2023)

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score
por: Li, Yongjiang, et al.
Publicado: (2022)

Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma
por: Zhang, Li, et al.
Publicado: (2022)

An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment
por: Du, Yingxi, et al.
Publicado: (2021)

Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy
por: Ding, Lei, et al.
Publicado: (2022)

Computational and In Vitro Analysis of Plumbagin’s Molecular Mechanism for the Treatment of Hepatocellular Carcinoma
por: Wei, Yanfei, et al.
Publicado: (2021)

The role of RNA modification in hepatocellular carcinoma
por: Feng, Qiang, et al.
Publicado: (2022)

Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma
por: Zhou, Zheng, et al.
Publicado: (2022)

Efferocytosis signatures as prognostic markers for revealing immune landscape and predicting immunotherapy response in hepatocellular carcinoma
por: Xu, Ke, et al.
Publicado: (2023)

A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma
por: Li, Yaoting, et al.
Publicado: (2023)

Identification of a novel lncRNA prognostic signature and analysis of functional lncRNA AC115619.1 in hepatocellular carcinoma
por: Gan, Binliang, et al.
Publicado: (2023)

Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking
por: Khan, Shakeel Ahmad, et al.
Publicado: (2022)

m7G regulator-mediated molecular subtypes and tumor microenvironment in kidney renal clear cell carcinoma
por: Chen, Mei, et al.
Publicado: (2022)

Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma
por: Tang, Xiaolong, et al.
Publicado: (2023)

Heterogeneity characterization of hepatocellular carcinoma based on the sensitivity to 5-fluorouracil and development of a prognostic regression model
por: Gu, Xinyu, et al.
Publicado: (2023)

RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma
por: Peng, Hao, et al.
Publicado: (2022)

Identification of a prognostic evaluator from glutamine metabolic heterogeneity studies within and between tissues in hepatocellular carcinoma
por: Bao, Jie, et al.
Publicado: (2023)

Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma
por: Ran, Yunsheng, et al.
Publicado: (2023)

Pathway-Based Drug Repositioning for Breast Cancer Molecular Subtypes
por: Mejía-Pedroza, Raúl A., et al.
Publicado: (2018)

Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
por: Fang, Hanyi, et al.
Publicado: (2021)

ARK5 promotes invasion and migration in hepatocellular carcinoma cells by regulating epithelial-mesenchymal transition
por: Ye, Zhiyu, et al.
Publicado: (2018)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Investigation of Hippo pathway-related prognostic lncRNAs and molecular subtypes in liver hepatocellular carcinoma
por: Su, Qiongfei, et al.
Publicado: (2023)

Gastroprotective mechanism of modified lvdou gancao decoction on ethanol-induced gastric lesions in mice: Involvement of Nrf-2/HO-1/NF-κB signaling pathway
por: Xie, Lei, et al.
Publicado: (2022)

Characterization of tumor microenvironment and programmed death-related genes to identify molecular subtypes and drug resistance in pancreatic cancer
por: Yu, Liang, et al.
Publicado: (2023)

Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs
por: Du, Fengxia, et al.
Publicado: (2022)

A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma
por: Mao, Da, et al.
Publicado: (2022)

Large-Scale Transcriptome Analysis Identified a Novel Cancer Driver Genes Signature for Predicting the Prognostic of Patients With Hepatocellular Carcinoma
por: Li, Gao, et al.
Publicado: (2021)

Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Integrated bioinformatics analysis uncovers characteristic genes and molecular subtyping system for endometriosis
por: Wang, Zhaowei, et al.
Publicado: (2022)

Constructing a molecular subtype model of colon cancer using machine learning
por: Zhou, Bo, et al.
Publicado: (2022)

Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs
por: He, Mingang, et al.
Publicado: (2022)

Prognosis-Related Molecular Subtypes and Immune Features Associated with Hepatocellular Carcinoma
por: Ye, Jiazhou, et al.
Publicado: (2022)

Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

Identification of angiogenesis-related subtypes, the development of prognostic models, and the landscape of tumor microenvironment infiltration in colorectal cancer
por: Zhang, Chen, et al.
Publicado: (2023)

Identification of molecular subtypes and prognostic signature for hepatocellular carcinoma based on genes associated with homologous recombination deficiency
por: Lin, Hongsheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0g02vg7e2m0l03083jdjpp263a